---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021189"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:08:46.978195+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera sells Xepi® license to Pelthos for up to $10M; receives $3M at close

## Summary
- Sold US license of Xepi® (ozenoxacin) cream to Pelthos Therapeutics for up to $10M total consideration.
- Received $3M cash at closing; additional $1M due upon availability of commercial product.
- Up to $6M in milestones: $3M each upon achieving $10M and $15M annual net sales of Xepi®.
- Company expects proceeds to fund operations to profitability, supporting Ameluz® PDT franchise.
- Transaction bolsters cash position after recent restructuring of agreement with Biofrontera AG.

## SEC filing metadata
- accession: 0001493152-25-021189
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315225021189/0001493152-25-021189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315225021189/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021189
- JSON: https://secwatch.observer/filing/0001493152-25-021189.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021189.txt

## Source-grounded claims
- claim_id: f3ebbf89df88eb178cd11dde793e6a2acc92e8af
  claim: Biofrontera Inc. completed a disposition involving Pelthos Therapeutics Inc. for maximum of $10,000,000 (closed 2025-11-06).
  evidence_excerpt: Capitalized terms used below that are not defined herein shall have the meanings ascribed to such terms in the APA. The purchase price for the Acquired Assets is a maximum of $10,000,000, payable as follows: 1) $3,000,000 in cash, paid on the Closing Date; 2) Subject to availability of certain commercial quantities of the Product and other terms and conditions of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315225021189/0001493152-25-021189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.